Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
The present study compared the extent and duration of MAO inhibition by the selective and reversible MAO-A inhibitor brofaromine with the selective and irreversible MAO-A inhibitor clorgyline using amine pressor tests and excretion of urinary amine metabolites (MHPG, tryptamine). The pharmacological characterization of clorgyline as an irreversible and brofaromine as a reversible MAO-A inhibitor in clinically effective doses was confirmed in humans.
Gleiter
C H
CH
Human Pharmacology Institute, Ciba-Geigy GmbH, Tübingen, Federal Republic of Germany.
Mühlbauer
B
B
Schulz
R M
RM
Nilsson
E
E
Antonin
K H
KH
Bieck
P R
PR
D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D003010:Clorgyline / Q000494:pharmacology*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007262:Infusions, Intravenous; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000652:urine; D008995:Monoamine Oxidase / Q000502:physiology*; D009638:Norepinephrine / Q000008:administration & dosage / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D012016:Reference Values; D014363:Tryptamines / Q000652:urine; D014439:Tyramine / Q000008:administration & dosage / Q000494:pharmacology*
D010880:Piperidines; D014363:Tryptamines; C030820:tryptamine; D008734:Methoxyhydroxyphenylglycol; C038213:brofaromine; D008995:Monoamine Oxidase; D003010:Clorgyline; D009638:Norepinephrine; D014439:Tyramine